Related Experiment Videos
Treatment requirements of infants with rhesus isoimmunisation within a geographically defined area
A Greenough1, G Hartnoll, H Hambley
1Department of Child Health, King's College Hospital, London, UK. anne.greenough@kcl.ac.uk
Insights
Few infants require treatment for rhesus isoimmunisation (RhD). This study found only 26 infants needed phototherapy or transfusions, with no fatalities, highlighting a low incidence of severe cases.
Area of Science:
- Neonatal care
- Pediatric hematology
- Obstetrics
Background:
- Rhesus isoimmunisation (RhD) is a condition where maternal antibodies target fetal red blood cells.
- Effective management and treatment protocols are crucial for preventing severe neonatal outcomes.
Purpose of the Study:
- To determine the population-based incidence of treatment requirements for infants with rhesus isoimmunisation.
- To provide data on the types and duration of treatments administered for this condition.
Main Methods:
- A prospective, population-based study was conducted across 29 hospitals in South Thames.
- Data were collected over a one-year period (February 1999 - January 2000) via monthly postcards and subsequent detailed information requests.
- Inclusion criteria focused on infants requiring postnatal treatment for rhesus isoimmunisation.
Main Results:
- Only 26 infants required treatment for rhesus isoimmunisation during the study year.
- The median phototherapy duration was 5 days; 7 infants needed exchange transfusions, and 7 received top-up transfusions.
- No infants received erythropoietin, and there were no reported deaths due to rhesus isoimmunisation.
Conclusions:
- The incidence of infants requiring treatment for rhesus isoimmunisation appears to be low.
- Current treatment strategies, including phototherapy and transfusions, were utilized, with no fatalities observed.
Objective:
To provide population based data on the treatment requirements of infants with rhesus isoimmunisation.
Setting:
Twenty nine hospitals in South Thames in which 81 119 deliveries occurred between February 1999 and January 2000.
Design:
Every month, a clinician identified in each of the hospitals sent back a postcard indicating whether or not an infant with RhD had required treatment in their institution. Antenatal and postnatal information was then requested from all those who gave positive responses.
Main Outcome Measures:
Requirement for postnatal treatment for rhesus isoimmunisation.
Results:
During the one year study period, only 26 infants required treatment for rhesus isoimmunisation. The median duration of phototherapy of the 26 infants was five days (range 1-12). Seven infants required at least one exchange transfusion (two required two exchange transfusions), and seven infants received one "top up" transfusion. None received erythropoietin and no infant died.
Conclusion:
The results suggest that few infants require treatment for rhesus isoimmunisation.